N
Niels F. M. Kok
Researcher at Netherlands Cancer Institute
Publications - 36
Citations - 1303
Niels F. M. Kok is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Hyperthermic intraperitoneal chemotherapy & Cancer. The author has an hindex of 10, co-authored 36 publications receiving 561 citations.
Papers
More filters
Journal ArticleDOI
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Myriam Chalabi,Lorenzo F. Fanchi,Krijn K. Dijkstra,José G van den Berg,Arend G. J. Aalbers,Karolina Sikorska,Marta Lopez-Yurda,Cecile Grootscholten,Geerard L. Beets,Geerard L. Beets,Petur Snaebjornsson,Monique Maas,Marjolijn Mertz,Vivien Veninga,Gergana Bounova,Annegien Broeks,Regina G. H. Beets-Tan,Regina G. H. Beets-Tan,Thomas R de Wijkerslooth,Anja U. van Lent,Hendrik A Marsman,Elvira Nuijten,Niels F. M. Kok,Maria Kuiper,Wieke H M Verbeek,Marleen Kok,Monique E. van Leerdam,Ton N. Schumacher,Emile E. Voest,John B. A. G. Haanen +29 more
TL;DR: The data indicate that neoadjuvant immunotherapy may have the potential to become the standard of care for a defined group of colon cancer patients when validated in larger studies with at least 3 years of disease-free survival data.
Journal ArticleDOI
Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial
Charlotte E. L. Klaver,Daniel D Wisselink,Cornelis J. A. Punt,Petur Snaebjornsson,Johannes Crezee,Arend G. J. Aalbers,Alexandra Brandt,A.J.A. Bremers,Jacobus W. A. Burger,Hans F. J. Fabry,Floris Ferenschild,Sebastiaan Festen,Wilhelmina M U van Grevenstein,Patrick H. J. Hemmer,Ignace H. J. T. de Hingh,Niels F. M. Kok,Gijsbert D. Musters,Lotte Schoonderwoerd,Jurriaan B. Tuynman,Anthony W. H. van de Ven,Henderik L van Westreenen,Marinus J. Wiezer,David D. E. Zimmerman,Annette A van Zweeden,Marcel G. W. Dijkgraaf,Pieter J. Tanis,Caroline S. Andeweg,Vivian P. Bastiaenen,Willem A. Bemelman,Jarmila D. W. van der Bilt,Johanne Bloemen,Frank C. den Boer,Djamila Boerma,Daan ten Bokkel Huinink,Walter J.A. Brokelman,Huib A. Cense,Esther C. J. Consten,Geert-Jan Creemers,Rogier M P H Crolla,J. W. T. Dekker,Jennifer Demelinne,Marc J. van Det,Karin K. van Diepen,Marjolein Diepeveen,Eino B. van Duyn,Esther D. van den Ende,Pauline Evers,Anna A. W. van Geloven,Erwin van der Harst,Jeroen Heemskerk,Joost T. Heikens,Daniel A. Hess,Bas Inberg,Jan Jansen,Frank W.H. Kloppenberg,Thomas J.M. Kootstra,R.T.J. Kortekaas,Maartje Los,Eva V. E. Madsen,H.C.J. van der Mijle,Linda Mol,P.A. Neijenhuis,Simon W. Nienhuijs,Loes van den Nieuwenhof,Koen C.M.J. Peeters,Sebastiaan W. Polle,Jolien Pon,Pieter Poortman,Sandra A Radema,Bert van Ramshorst,Philip R. de Reuver,Koen P. Rovers,Roderick F. Schmitz,Nina R. Sluiter,Dirkje W. Sommeijer,D. J. A. Sonneveld,T.C. van Sprundel,Sanne C. Veltkamp,Maarten Vermaas,Victor J. Verwaal,Emma C. E. Wassenaar,Johannes A. Wegdam,Johannes H. W. de Wilt,M. Westerterp,Fennie Wit,Arjen J. Witkamp,Karlijn van Woensdregt,Edwin S. van der Zaag,Mandy Zournas +88 more
TL;DR: In patients with T4 or perforated colon cancer, treatment with adjuvant HIPEC with oxaliplatin did not improve peritoneal metastasis-free survival at 18 months, and there was no difference in peritonealan metastasis free-survival in the intention-to-treat population.
Journal ArticleDOI
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)
Koen P. Rovers,Checca Bakkers,Geert A. Simkens,Jacobus W. A. Burger,Simon W. Nienhuijs,Geert-Jan Creemers,Anna M. J. Thijs,Alexandra R. M. Brandt-Kerkhof,Eva V. E. Madsen,Ninos Ayez,Nadine L. de Boer,Esther van Meerten,Jurriaan B. Tuynman,Miranda Kusters,Nina R. Sluiter,Henk M.W. Verheul,Hans van Vliet,Marinus J. Wiezer,Djamila Boerma,Emma C. E. Wassenaar,Maartje Los,Cornelis B. Hunting,Arend G. J. Aalbers,Niels F. M. Kok,Koert F. D. Kuhlmann,Henk Boot,Myriam Chalabi,Schelto Kruijff,Lukas B. Been,Robert J. van Ginkel,Derk Jan A. de Groot,Rudolf S N Fehrmann,Johannes H. W. de Wilt,Andreas J A Bremers,Philip R. de Reuver,Sandra A Radema,K. H. Herbschleb,Wilhelmina M U van Grevenstein,Arjen J. Witkamp,Miriam Koopman,Nadia Haj Mohammad,Eino B. van Duyn,Walter J.B. Mastboom,Leonie J. M. Mekenkamp,Joost Nederend,Max J. Lahaye,Petur Snaebjornsson,Cornelis Verhoef,Hanneke W. M. van Laarhoven,Aeilko H. Zwinderman,Jeanette M. Bouma,Onno Kranenburg,Iris van 't Erve,Remond J.A. Fijneman,Marcel G. W. Dijkgraaf,Patrick H. J. Hemmer,Cornelis J. A. Punt,Pieter J. Tanis,Ignace H. J. T. de Hingh +58 more
TL;DR: This is the first randomised study that prospectively compares oncological outcomes of perioperative systemic therapy and CRS-HIPEC with upfront C RS-HipEC alone for isolated resectable colorectal PM.
Journal ArticleDOI
Hyperspectral imaging for tissue classification, a way toward smart laparoscopic colorectal surgery.
Elisabeth J. M. Baltussen,Esther N D Kok,Susan G. Brouwer de Koning,Joyce Sanders,Arend G. J. Aalbers,Niels F. M. Kok,Geerard L. Beets,Claudie C Flohil,Sjoerd Bruin,Koert F. D. Kuhlmann,Henricus J. C. M. Sterenborg,Henricus J. C. M. Sterenborg,Theo J.M. Ruers,Theo J.M. Ruers +13 more
TL;DR: The potential of using HSI in colorectal cancer surgery for fast tissue classification, which could improve clinical outcome is shown.
Journal ArticleDOI
Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
Daan D. Wisselink,Linde L.F. Braakhuis,Gaetano Gallo,Wilhelmina M U van Grevenstein,Susan van Dieren,Niels F. M. Kok,Philip R. de Reuver,Pieter J. Tanis,Ignace H. J. T. de Hingh +8 more
TL;DR: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints.